Continuous ambulatory peritoneal dialysis: no longer experimental.

Area of Science:

• Nephrology
• Renal Medicine
• Dialysis Therapies

Background:

• Continuous ambulatory peritoneal dialysis (CAPD) evolved from an experimental option to a preferred treatment for end-stage renal disease (ESRD).
• Initial concerns regarding peritonitis frequency have significantly decreased with improved management protocols.

Purpose of the Study:

• To evaluate the long-term efficacy and outcomes of CAPD in patients with end-stage renal disease.
• To identify patient populations that benefit most from CAPD and to understand its associated complications.

Main Methods:

• Long-term patient data analysis for continuous ambulatory peritoneal dialysis (CAPD) in end-stage renal disease (ESRD) management.
• Comparative assessment of outcomes, including survival rates, complication incidence, and specific health improvements.

Main Results:

• CAPD is suitable for self-care and has shown reduced peritonitis rates (1 episode per 18 patient-months).
• Chronic complications such as malnutrition and ultrafiltration loss are now more apparent.
• Survival rates are lower in elderly patients and those with heart disease or diabetes, but CAPD improves hypertension control, anemia, and growth in children.

Conclusions:

• CAPD is a feasible and effective long-term treatment for end-stage renal disease, offering distinct advantages for specific patient groups.
• While peritonitis is less frequent, ongoing monitoring for chronic complications is essential for optimizing patient care and outcomes.